Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California


This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.


Inclusion Criteria: - Male or female 12 years and above - Clinical diagnosis of asthma according to the American Thoracic Society definition at least 6 months - Pre-bronchodilator FEV1 ≥ 45% and ≤ 85% of predicted normal - Patients with reversible airway obstruction - Documented daily use of inhaled corticosteroids for ≥ 3 months Exclusion Criteria: - History of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures during the 2 years prior to Visit 2 - Hospitalized during previous 6 months for asthma - Required emergency treatment more than once during previous 6 months for an asthma-related condition - Intake of oral, rectal or parenteral glucocorticosteroid within 30 days of enrolment - Respiratory infection affecting the asthma within 30 days



Primary Contact:

Study Director
Goran Eckerwall, MD
AstraZeneca R&D, Mölndal

Backup Contact:


Location Contact:

Los Angeles, California
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.